BTIG downgraded Entellus Medical (NASDAQ:ENTL) to “neutral” from “buy,” saying that “something has gone off course” after the company reported Q4 results on Feb. 21. The stock closed at $17.08 yesterday.Read More
Mackie Research Capital raised its price target for Profound Medical (TSX-V:PRN) to $4.40 from $3.30 after the company reported third quarter results. The stock closed at $1 on Thursday.
Analyst Andre Uddin writes that his new valuation is based on applying a multiple of 4.2 times enterprise value to sales on a 2019 sales estimate to $86-million, discounted back by 50%.Read More
MP Securities resumed coverage of AtriCure (NASDAQ:ATRC) with a “market outperform” rating and $25 price target. The stock closed at $14.39 on Wednesday.
“AtriCure is well positioned, in our view, to further develop and penetrate several large opportunities that are currently underserved in and around atrial fibrillation (AF),” writes analyst John Gillings.Read More